Overcoming cancer drug resistance

Pipeline

Cancer drug resistance

INVESTORS

Interim Report Q1 2022

Rights Issue 2022

Read more

Interim Report Q1 2022

President & CEO Bo Rode Hansen reflects on our achievements and outlook for 2022

PRESS RELEASES

Invitation to Scandion Oncology webcast and conference call August 25, 2022

Scandion Oncology (Scandion) will publish its Q2 2022 interim report on Thursday, August 25, 2022 before 09:00 CET. Scandion’s Executive Management will host a webcast and conference call the same day at 10:00 CET presenting the results and a company update. At the end of the presentation there will be a Q&A session. Access to the event c …

Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101

Good tolerability allows for continued dose escalation in the dose-finding PANTAX phase 1b-trial with SCO-101 as combination therapy in pancreatic cancer. Consequently, readout from the trial is now expected in the first half of 2023.

Scandion Oncology announces share purchase by Board of Directors

Member of the Board of Directors has purchased shares in the company.

View all press releases

UPCOMING EVENTS

Interim report Q2 2022

Scandion Oncology (Scandion) will publish its Q2 2022 interim report on Thursday, August 25, 2022 before 09:00 CET. Scandion’s Executive Management will host a webcast and conference call the same day at 10:00 CET presenting the results and a company update. At the end of the presentation there will be a Q&A session. Access to the event can be …

LSX Nordic Congress

Meet Scandion Oncology at LSX Nordic 2022

ChinaBIO Partnering Forum 2022

Meet Scandion Oncology at ChinaBio® Partnering Forum 2022

View all upcoming events

Learn more about our unique first-in-class lead compound SCO-101

Read more about SCO-101

LATEST PRESENTATIONS

Redeye Transactions

Watch President & CEO Bo Rode Hansen’s presentation from Redeye Transactions

Aktiespararna

Watch Chief Operating Officer Maj Hedtjärn present Scandion at Aktiespararna Småbolagsdagarna 2022

DAF Interview

Watch President and CEO Bo Rode Hansen present Scandion to The Danish Shareholder Association

View all presentations

INVESTOR

Scandion Oncology Capital Markets Day

September 8, 2021

Watch the presentations from Scandion Oncology’s Capital Markets Day

Capital Markets Day View all presentations

CAREER

A great place to work

For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatments